ArticleIndian dermatology online journal2026
Oral Tofacitinib versus Azathioprine in the Management of Chronic Actinic Dermatitis - An Open Randomized Clinical Trial.
Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic actinic dermatitis (CAD) is an immunologically mediated photodermatosis characterized by pruritic eczematous and lichenified plaques located predominantly on sun-exposed areas with notable sparing of eyelids, skin folds, and postauricular skin. Tofacitinib is a Janus kinase inhibitor, and azathioprine is a purine analog. This study aimed to compare the role of tofacitinib versus azathioprine in the management of CAD. AIM AND
objectivesTo compare the efficacy and tolerability of tofacitinib versus azathioprine in the management of CAD. PATIENTS AND
methodsThe study involved 30 patients above 18 years of age diagnosed with CAD. Group A received azathioprine 100 mg daily with topical emollients, while group B received oral tofacitinib 5 mg twice daily with topical emollients, both for 90 days. Efficacy was assessed using Eczema Area Severity Index (EASI) score and photographic analysis, with 50% reduction in EASI (EASI50) as the endpoint.
resultsThere was a 30.85% reduction in the mean EASI score in the azathioprine group as compared to 57.2% in the tofacitinib group (P=0.018). In the tofacitinib group, 80% of patients achieved the primary endpoint of EASI50, compared to 20% of patients achieving the same in the azathioprine group. Adverse effects were reported more in the azathioprine group as compared to the tofacitinib group ( P = 0.003). LIMITATIONS: A small sample size, lack of assessment of improvement in quality of life, and the patients were followed up for 90 days only. Conclusion: Tofacitinib is more efficacious and better tolerated than azathioprine in the management of CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.